OncoSil Medical Limited: Difference between revisions
Created page with "OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and bile duct cancer in Australia. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy. The company was formerly known as NeuroDiscovery Limited and changed its name t..." |
No edit summary |
||
| Line 1: | Line 1: | ||
== Summary == | |||
OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and bile duct cancer in Australia. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy. The company was formerly known as NeuroDiscovery Limited and changed its name to OncoSil Medical Limited in May 2013. OncoSil Medical Limited was incorporated in 2005 and is headquartered in North Sydney, Australia. | OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and bile duct cancer in Australia. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy. The company was formerly known as NeuroDiscovery Limited and changed its name to OncoSil Medical Limited in May 2013. OncoSil Medical Limited was incorporated in 2005 and is headquartered in North Sydney, Australia. | ||
Revision as of 16:51, 13 August 2022
Summary
OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and bile duct cancer in Australia. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy. The company was formerly known as NeuroDiscovery Limited and changed its name to OncoSil Medical Limited in May 2013. OncoSil Medical Limited was incorporated in 2005 and is headquartered in North Sydney, Australia.